Cancer risk in systemic lupus: An updated international multi-centre cohort study

Sasha Bernatsky*, Rosalind Ramsey-Goldman, Jeremy Labrecque, Lawrence Joseph, Jean Francois Boivin, Michelle Petri, Asad Zoma, Susan Manzi, Murray B. Urowitz, Dafna Gladman, Paul R. Fortin, Ellen Ginzler, Edward Yelin, Sang Cheol Bae, Daniel J. Wallace, Steven Edworthy, Soren Jacobsen, Caroline Gordon, Mary Anne Dooley, Christine A. PeschkenJohn G. Hanly, Graciela S. Alarcón, Ola Nived, Guillermo Ruiz-Irastorza, David Isenberg, Anisur Rahman, Torsten Witte, Cynthia Aranow, Diane L. Kamen, Kristjan Steinsson, Anca Askanase, Susan Barr, Lindsey A. Criswell, Gunnar Sturfelt, Neha M. Patel, Jean Luc Senécal, Michel Zummer, Janet E. Pope, Stephanie Ensworth, Hani El-Gabalawy, Timothy McCarthy, Lene Dreyer, John Sibley, Yvan St. Pierre, Ann E. Clarke

*Corresponding author for this work

Research output: Contribution to journalArticle

153 Scopus citations

Abstract

Objective: To update estimates of cancer risk in SLE relative to the general population. Methods: A multisite international SLE cohort was linked with regional tumor registries. Standardized incidence ratios (SIRs) were calculated as the ratio of observed to expected cancers. Results: Across 30 centres, 16,409 patients were observed for 121,283 (average 7.4) person-years. In total, 644 cancers occurred. Some cancers, notably hematologic malignancies, were substantially increased (SIR 3.02, 95% confidence interval, CI, 2.48, 3.63), particularly non-Hodgkin's lymphoma, NHL (SIR 4.39, 95% CI 3.46, 5.49) and leukemia. In addition, increased risks of cancer of the vulva (SIR 3.78, 95% CI 1.52, 7.78), lung (SIR 1.30, 95% CI 1.04, 1.60), thyroid (SIR 1.76, 95% CI 1.13, 2.61) and possibly liver (SIR 1.87, 95% CI 0.97, 3.27) were suggested. However, a decreased risk was estimated for breast (SIR 0.73, 95% CI 0.61-0.88), endometrial (SIR 0.44, 95% CI 0.23-0.77), and possibly ovarian cancers (0.64, 95% CI 0.34-1.10). The variability of comparative rates across different cancers meant that only a small increased risk was estimated across all cancers (SIR 1.14, 95% CI 1.05, 1.23). Conclusion: These data estimate only a small increased risk in SLE (versus the general population) for cancer over-all. However, there is clearly an increased risk of NHL, and cancers of the vulva, lung, thyroid, and possibly liver. It remains unclear to what extent the association with NHL is mediated by innate versus exogenous factors. Similarly, the etiology of the decreased breast, endometrial, and possibly ovarian cancer risk is uncertain, though investigations are ongoing.

Original languageEnglish (US)
Pages (from-to)130-135
Number of pages6
JournalJournal of Autoimmunity
Volume42
DOIs
StatePublished - May 2013

Keywords

  • Disease activity
  • Epidemiology
  • Systemic lupus erythematosus
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Cancer risk in systemic lupus: An updated international multi-centre cohort study'. Together they form a unique fingerprint.

  • Cite this

    Bernatsky, S., Ramsey-Goldman, R., Labrecque, J., Joseph, L., Boivin, J. F., Petri, M., Zoma, A., Manzi, S., Urowitz, M. B., Gladman, D., Fortin, P. R., Ginzler, E., Yelin, E., Bae, S. C., Wallace, D. J., Edworthy, S., Jacobsen, S., Gordon, C., Dooley, M. A., ... Clarke, A. E. (2013). Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 42, 130-135. https://doi.org/10.1016/j.jaut.2012.12.009